(Press-News.org) Impaired function of lung fibroblast is considered causative for symptoms of the incurable lung disease COPD (Chronic Obstructive Pulmonary Disease). Using high-resolution epigenetic profiling, German and British scientists have now identified potential targets for COPD treatment. The team detected early epigenetic changes in the genome of COPD fibroblasts, providing new insights into the disease pathogenesis and potential therapeutic avenues.
COPD, affecting approximately 600 million people globally, is characterized by chronic inflammation, progressive airway narrowing, and alveolar destruction. Despite its global prevalence, the molecular mechanisms driving lung fibroblast dysfunction in COPD have remained elusive. "For example, we know that smoking - the main risk factor for COPD – strongly modifies the epigenome of lung cells. However, we do not yet know which epigenetic changes occur specifically in lung fibroblasts during the course of the disease, and how these changes trigger aberrant signalling pathways that drive the impaired functions of fibroblasts in COPD," says Maria Llamazares-Prada from the German Cancer Research Center (DKFZ), one of the first authors of the current study.
Changes in cellular programs are controlled by a variety of epigenetic modifications. These chemical marks influence which genes are read and which are not. The best studied epigenetic mechanism is the attachment of methyl groups to DNA. Methylation changes in COPD have been studied previously, but mostly in mixed cell populations. Together with colleagues from the University of Cardiff, the Translational Lung Research Center, Boehringer Ingelheim and the BioMedX Institute in Heidelberg, Uwe Schwartz, Llamazares and colleagues have now analyzed for the first time the methylome of isolated COPD fibroblasts at high resolution across different disease stages. The researchers found that significant methylation changes occur early in the disease, particularly in regulatory regions of the genome. Proteins that activate or inhibit transcription bind to these altered regions, potentially affecting the expression of several genes.
Crucially, the team identified that regions with changed methylation patterns contain binding sites for transcription factors TCF21 and FOSL2/FRA2, which regulate key fibroblast processes associated with COPD. This discovery, combined with the integration of DNA methylation and gene expression data, led to the selection of 110 candidate genes that may regulate these changes in COPD fibroblasts.
Senior author, Renata Z. Jurkowska, Cardiff University (UK), stated, "Our aim was to support the development of new diagnostic strategies for early COPD and the rational selection of targets with potential disease-modifying activities. Further research is needed to pinpoint the target genes of the identified regulators in lung fibroblasts and their specific role in disease development." The findings open a new window into understanding the epigenetic underpinnings of COPD and may lead to innovative treatment approaches for this incurable disease.
Uwe Schwartz, Maria Llamazares Prada, Stephanie T Pohl, Mandy Richter, Raluca Tamas, Michael Schuler, Corinna Keller, Vedrana Mijosek, Thomas Muley, Marc A Schneider, Karsten Quast, Joschka Hey, Claus P Heußel, Arne Warth, Hauke Winter, Özdemirhan Sercin, Harry Karmouty-Quintana , Soma SK Jyothula, Manish K Patel, Felix Herth, Ina Koch, Giuseppe Petrosino , Alexandru Titimeaua, Balca R Mardin, Dieter Weichenhan, Tomasz P Jurkowski, Charles D Imbusch, Benedikt Brors, Vladimir Benes, Birgit Jung, David Wyatt, Heiko F Stahl, Christoph Plass & Renata Z Jurkowska: High-resolution transcriptomic and epigenetic profiling identifies novel regulators of COPD EMBO Journal 2023, DOI: 10.15252/embj.2022111272
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.
To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:
National Center for Tumor Diseases (NCT, 6 sites)
German Cancer Consortium (DKTK, 7 sites)
Hopp Children's Cancer Center (KiTZ) Heidelberg
Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.
Epigenetic profiling identifies potential COPD treatment targets
ELSE PRESS RELEASES FROM THIS DATE:
CHOP researchers comprehensively assess the safety of using your head in youth soccer
Philadelphia, May 24, 2023 – Repeatedly heading a soccer ball has been previously associated with negative long-term brain health for professional players. However, in a new study from researchers at the Minds Matter Concussion Program at Children’s Hospital of Philadelphia (CHOP), a small number of repeated soccer headers equivalent to a throw-in did not cause immediate neurophysiological deficits for teens, suggesting that limited soccer heading exposure in youth sports may not result in irreversible harm if players are properly trained. The ...
Case study reveals potentially lethal side effects of lecanemab for treatment of Alzheimer's disease
Amsterdam, May 24, 2023 – In a noteworthy case study published in the Journal of Alzheimer’s Disease investigators report autopsy findings in a 65-year-old woman with Alzheimer’s disease (AD) who received three open label infusions of the experimental anti-amyloid beta (Aβ) antibody drug lecanemab. Four days after the last infusion, she experienced stroke symptoms and died several days later due to multifocal intracerebral hemorrhage despite attempts at therapeutic intervention. Neuropathologic findings reflected ...
How can universities better understand students’ experiences of violence and victimisation?
Researchers from City, University of London, in collaboration with the University of Surrey, De Montfort University, Universities UK (UUK) and the National Centre (NatCen) for Social Research have conducted the first pilot study into students’ experiences of all forms of violence and victimisation at UK universities. The Violence at University project, led by Dr Carrie-Anne Myers, Reader in the Department of Sociology and Criminology at City, aimed to investigate whether an effective tool could be developed for tracking when, where and how incidents take place. Tackling violence and harassment has been high on universities’ agenda for several years. Hate crime has ...
Use of AI: Placebo effect increases risk-taking
Human augmentation technologies refer to technological aids that enhance human abilities. They include things like exoskeletons, but also augmented reality headsets. A study at the Chair of Human-Centered Ubiquitous Media at LMU has now shown that users have high expectations of the effects of these technologies. As soon as they believe that AI is enhancing their cognitive abilities, they increase their risk-taking. And they do this independently of whether the AI is actually assisting them. “The hype around AI applications affects the expectations of users. This can lead to riskier behavior,” says Steeven Villa, doctoral researcher ...
Mixing metals for improved performance
NEWPORT NEWS, VA – A teenage fascination with metals has led to a prestigious early-career award for a superconducting radiofrequency (SRF) materials scientist at the U.S. Department of Energy’s Thomas Jefferson National Accelerator Facility. Shreyas Balachandran has been chosen to receive the ICMC Cryogenic Materials Award for Excellence, presented annually to an individual under 40 who has demonstrated innovation, impact and international recognition for their work in advancing the knowledge of cryogenic materials. “It’s ...
SwRI’s Dr. Peter Lee named STLE Fellow
SAN ANTONIO — May 24, 2023 —Dr. Peter Lee of Southwest Research Institute’s Tribology Research and Evaluations Section has been named a Fellow of the Society of Tribologists and Lubrication Engineers (STLE). An STLE fellowship recognizes society members with significant contributions over 20 years of active practice in the field of tribology and lubrication engineering. These contributions must meet a standard considered by STLE above and beyond those typically expected of a scientist or engineer. Tribology is the study of lubrication, friction ...
Phytophthora “the plant destroyer” meets its match with a new identification tool
Known as the “plant destroyer,” the genus Phytophthora is considered one of the most important groups of plant pathogens—causing significant economic and environmental losses throughout history and into today. There are over 200 identified species in the Phytophthora genus. These pathogens, and those yet to be identified, can spread quickly due to the increasing rate of global trade, e-commerce, and travel. Rapid identification is therefore critical for effective plant disease management. While several international online resources for Phytophthora identification ...
Engineers at UMass Amherst harvest abundant clean energy from thin air, 24/7
Researchers describe the “generic Air-gen effect”—nearly any material can be engineered with nanopores to harvest, cost effective, scalable, interruption-free electricity AMHERST, Mass. – A team of engineers at the University of Massachusetts Amherst has recently shown that nearly any material can be turned into a device that continuously harvests electricity from humidity in the air. The secret lies in being able to pepper the material with nanopores less than 100 nanometers in diameter. The research appeared in the journal Advanced Materials. “This is very exciting,” ...
Multifunctional interface enables manipulation of light waves in free space
Recent technological advances have given us a remarkable ability to manipulate and control light waves, opening up numerous applications in various fields, such as optical communication, sensing, imaging, energy, and quantum computing. At the heart of this progress are photonic structures that can control light waves, either at the chip level in the form of photonic integrated circuits (PICs) or in free space as meta-optics. Combining these structures allows for the creation of compact optical systems. The PICs can be used to make subtle changes to the light wave, ...
Harvard professor and entrepreneur Tim Springer donates $210 million to the Institute for Protein Innovation
BOSTON, March 29, 2023 — The Institute for Protein Innovation (IPI), a nonprofit research organization, announced today a $210 million gift from Tim Springer, Ph.D., veteran entrepreneur and professor at Harvard Medical School and Boston Children’s Hospital, who founded IPI in 2017 with Andrew Kruse, Ph.D. The gift will advance protein science and accelerate research to improve human health. The philanthropic gift—made by Springer, his wife Chafen Lu, Ph.D., and their children—adds ...